WINNIPEG, MANITOBA--(Marketwire - Oct 10, 2012) - Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce that the Company has successfully developed the manufacturing process and completed the pilot scale production of the Company''s StrixNB Pet Oral Care product. StrixNB is a patent pending oral care product comprising a unique synergistic combination of food grade ingredients that have both the synergistic antimicrobial and antibiofilm activity against oral bacteria.
Four separate pilot manufacturing runs were conducted during the scale up following the required quality control procedures. The successful pilot production confirms the scale up feasibility for commercial production of StrixNB at a very favourable cost of goods which moves the Company closer to market launch.
The pilot scale manufacturing was conducted by the Richardson Centre for Functional Foods and Nutraceuticals (RCFFN) in Winnipeg, Manitoba. The RCFFN has unique capability, equipment and expertise in assisting companies moving their manufacturing process from the lab bench to commercial scale up.
"Pilot manufacturing and scalable production is an important step and confirms that we can scale up production to meet commercial volumes of our scientifically formulated product, as we prepare for a market entry", stated Gord Froehlich, President and CEO of Kane Biotech.
About The Richardson Centre for Functional Foods and Nutraceuticals.
The Richardson Centre for Functional Foods and Nutraceuticals is a bioprocessing and product development facility dedicated to the discussion, discovery, and development of functional foods and nutraceuticals. The Centre is available to agri-food, natural health product, and pharmaceutical industries to determine structure, function, efficacy, and safety of functional foods and nutraceuticals, as well as to evaluate products in controlled animal and human studies for potential health claims and palatability. The Centre has expertise and equipment to move from prototype to pilot plant to ensure processes are fully scalable and optimal for commercial activity.
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the development and commercialization of products to prevent and remove biofilms. Biofilms are a major cause of a number of serious medical problems including chronic infections and medical device related infections. They develop on surfaces such as catheters, prosthetic implants, teeth, lungs and the urogenital tract. Biofilms are pervasive, costly to deal with and are involved in approximately 80% of all human bacterial infections. The healing of chronic wounds alone costs the United States health care system $20 Billion per year.
Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.
These statements reflect management''s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane''s early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers'' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane''s filings with Canadian securities regulatory authorities, as well as Kane''s ability to anticipate and manage the risks associated with the foregoing. Kane cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Kane''s forward-looking statements to make decisions with respect to Kane, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.
These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane cannot provide assurance that actual results will be consistent with these forward-looking statements. Kane undertakes no obligation to update or revise any forward-looking statement.